Product Description
Capravirine is a non-nucleoside reverse transcriptase inhibitor. Capravirine shows antiviral activity against wild-type HIV as well as HIV strains with mutations in reverse transcriptase. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Capravirine)
Mechanisms of Action: NNRT Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Agouron
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: HIV Infections|Acquired Immunodeficiency Syndrome
Phase 1: HIV Infections|Acquired Immunodeficiency Syndrome|Deficiency Diseases|Communicable Diseases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00005673 |
00-I-0129 | P1 |
Completed |
HIV Infections |
None |
2019-03-21 |
Treatments |
|
NCT00006519 |
01-C-0025 | P1 |
Completed |
Acquired Immunodeficiency Syndrome|HIV Infections|Communicable Diseases|Deficiency Diseases |
None |
2019-03-21 |
Treatments |
|
NCT00002214 |
286A | P1 |
Completed |
Acquired Immunodeficiency Syndrome|HIV Infections|Deficiency Diseases|Communicable Diseases |
None |
2019-03-21 |
Treatments |
|
NCT00004985 |
286D | P2 |
Completed |
HIV Infections |
None |
2019-03-21 |
Treatments |
|
NCT00052117 |
A4311006 | P2 |
Completed |
HIV Infections |
None |
2019-03-21 |
Treatments |
|
NCT00051844 |
A4311002 | P2 |
Completed |
HIV Infections|Acquired Immunodeficiency Syndrome |
None |
2019-03-21 |
Treatments |
|
NCT00006211 |
286E | P2 |
Completed |
HIV Infections |
None |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|